According to our latest market study on “Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Technology, Application, End User, and Geography,” the market is expected to grow from US$ 18.23 billion in 2021 to US$ 54.62 billion by 2028; it is expected to grow at a CAGR of 11.7% from 2022 to 2028.
In light of item, , the market is portioned into consumables (antibodies, packs and reagents, tests, and other consumables) and instruments [pathology-based instruments (slide staining frameworks, tissue handling frameworks, cell processors, PCR instruments, NGS instruments, microarrays, and other), imaging instruments (CT frameworks, ultrasound frameworks, X-ray frameworks, mammography frameworks, atomic imaging frameworks, and biopsy instrument), and biopsy instruments]. The consumables portion held a bigger piece of the pie in 2021, and holding its strength during the conjecture period is normal. Expanding interest for consumables in disease diagnostics, trailed by the ascent in Research and development, is the key variable advancing the development of the market.
Get Sample PDF: https://www.theinsightpartners.com/sample/TIPMD00002290/
In light of use, the malignant growth diagnostics market is sectioned into bosom disease, cellular breakdown in the lungs, colorectal malignant growth, melanoma, and other malignant growth. The bosom disease fragment held the biggest piece of the pie in 2021. Bosom malignant growth is the most widely recognized disease across the world and the second-driving reason for death in the US.
As per WHO, almost 290,560 ladies were determined to have bosom disease in the US in 2022. A colossal portion of this piece can be certify because of the rising number of bosom malignant growth cases worldwide.
In view of end client, the malignant growth diagnostics market is fragmented into emergency clinics and analytic labs/focuses. The clinic portion represented over 60% of the piece of the pie in 2021 and is probably going to observe a quicker development during the gauge time frame. Rise of cutting edge medical services offices in non-industrial nations is the central point driving the development of the market.
GE Medical services, Abbott Research centers, Hologic Inc., Agilent Advancements Inc., Roche Diagnostics, FUJIFILM Partnership, Danaher Enterprise, DiaSorin S.P.A., Heap Hereditary qualities Inc., Siemens Healthineers AG, BD, bioMérieux SA, Bio-Rad Labs, Malignant growth Diagnostics Inc., Vela Diagnostics, Roche Diagnostics, AMOY Diagnostics CO. LTD., Quidel Organization, Bio SB, Biocartis NV, and Definite Science are the vital participants profiled during the investigation of the malignant growth diagnostics market. A few other significant organizations were examined during this review to get a comprehensive perspective on the malignant growth diagnostics market and its biological system.
Read More: https://www.theinsightpartners.com/reports/cancer-diagnostics-market
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876